Br[C:2]1[CH:7]=[C:6]([NH:8][C:9](=[O:20])[C:10]2[C:15]([Cl:16])=[CH:14][C:13]([CH:17]=[CH2:18])=[CH:12][C:11]=2[Cl:19])[CH:5]=[CH:4][N:3]=1.[CH:21]1([C:24]([NH2:26])=[O:25])[CH2:23][CH2:22]1.CC1(C)C2C(=C(P(C3C=CC=CC=3)C3C=CC=CC=3)C=CC=2)OC2C(P(C3C=CC=CC=3)C3C=CC=CC=3)=CC=CC1=2.C([O-])([O-])=O.[Cs+].[Cs+]>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[Cl:19][C:11]1[CH:12]=[C:13]([CH:17]=[CH2:18])[CH:14]=[C:15]([Cl:16])[C:10]=1[C:9]([NH:8][C:6]1[CH:5]=[CH:4][N:3]=[C:2]([NH:26][C:24]([CH:21]2[CH2:23][CH2:22]2)=[O:25])[CH:7]=1)=[O:20]A solution of N-(2-bromopyridin-4-yl)-2,6-dichloro-4-vinylbenzamide (23 mg, 0.062 mmol), cyclopropanecarboxamide (16 mg, 0.19 mmol), Pd2(dba)3 (6.0 mg, 0.0062 mmol), Xantphos (7.0 mg, 0.012 mmol) and Cs2CO3 (40 mg, 0.12 mmol) in dioxane (2 mL) was heated to 140° C. for 1 hour in a microwave reactor under nitrogen atmosphere. The mixture was filtered through Celite and concentrated under reduced pressure. The residue was purified by prep-HPLC (Gilson GX 281, Shim-pack PRC-ODS 250 mm×20 mm×2, gradient: CH3CN/10 mm/L NH4HCO3, 17 min) to afford 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)-4-vinylbenzamide (10 mg, yield: 43%). 1H NMR (500 MHz, CDCl3): δ 8.26 (s, 1H), 7.99-7.97 (m, 2H), 7.74 (s, 1H), 7.37 (s, 2H), 6.64 (m, 1H), 5.86 (m, 1H), 5.47 (m, 1H), 1.52 (m, 1H), 1.09-1.05 (m, 2H), 0.92-0.88 (m, 2H). LCMS (ESI) m/z: 376.1 [M+H+].